MedWatch

Committee declines reimbursement for Novo's obesity drug

The price of Novo Nordisk's obesity drug Saxenda does not match the efficiency. This is according to the Danish Medicines Agency's reimbursement committee that declines reimbursement of the therapy for Danish patients without an exceptional explanation.

Foto: colourbox

Edit: The price mentioned in paragraph 4 has been corrected from 34 DKK to 63 DKK

Danish patients may have to pay the full price themselves if they wish to be treated with Novo Nordisk's obesity drug Saxenda (liraglutide).

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier